Tuesday, November 18, 2014 4:39:45 PM
The exVive3D™ Liver Model: Organovo Delivers its 3D Printed Livers
Michael Molitch-Hou BY MICHAEL MOLITCH-HOU ON TUE, NOVEMBER 18, 2014 · 3D PRINTING, BUSINESS, INDUSTRY NEWS, MEDICAL & DENTAL ADD COMMENT
39
SHARES
Share on Facebook Share on Twitter Share on Google+ +
In some ways, today may be a day looked back on as a turning point in medical history. Organovo (NASDAQ: ONVO), the first company to market 3D bioprinting technology, has announced the sale of its bioprinted livers, called the exVive3D™ Liver Model. Though too small to be considered an actual organ, the 3D printed exVive3D™ Liver Model has the potential to radically change the field of medicine.
Pioneer of the 3D bioprinting business Organovo has been researching the field since 2007, first developing their NovoGen MMX Bioprinter and then using their bioprinting process to begin 3D printing samples of living human tissue. After successfully creating a viable liver assay, the company announced that sometime in 2014, they would release their first product, a 3D printed liver for drug testing purposes.
organovo 3D bioprinting new drug discovery
Between now and then, Organovo proved that their liver cells could not only live for a substantial amount of time, but that they also demonstrated liver functions key to drug testing. The liver cells were able to show a toxic response in the presence of known toxins, like Acetaminophen. This proved that the cells could potentially be used to test the toxicity levels of drugs currently being developed by pharmaceutical manufacturers. To get it to market, Organovo first had to find third-party researchers to independently test the viability and effectiveness of their liver cells. Now that pharma companies Janssen Research and Development (JRD) and Roche Pharmaceuticals have verified the product, Organovo has officially launched the 3D printed liver.
The exVive3D™ Liver Model is not big enough to be considered an organ, but works in the same that a real liver might and lives up to 40 days or longer, making it ideal for testing the toxicity of new medications. The Organovo press release points out that “Since 2007, 16 drugs have been withdrawn from the market due to safety issues. It costs more than $1 billion and takes more than 12 years to bring to bring a drug to market.” Current 2D liver assays can’t provide a realistic environment for testing purposes and die in only a few days. In their retrospective study, however, Roche and Organovo found that only the exVive was able to identify a formerly FDA-approved drug, later removed from the market, as toxic.
Organovo CEO, Keith Murphy, said of the new product, “Pharma companies can use our bioprinted liver tissue to weed out toxic drugs early in drug development rather than after they have failed expensive clinical trials.” One day, such products could, in addition to improving drug safety, bypass the need for animal testing in medicine research as well. For more information about the bioprinting process, watch the video below.
And to hear more on the company’s role in medicine and 3D printing, watch 3DPI’s interview with Keith Murphy at the Inside 3D Printing event in Santa Clara embedded here:
Recent ONVO News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/18/2024 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:05:26 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 07/26/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:05:07 PM
- Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis • GlobeNewswire Inc. • 07/16/2024 12:05:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 05/31/2024 08:05:33 PM
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease • GlobeNewswire Inc. • 05/21/2024 12:05:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/14/2024 04:45:20 PM
- Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) • GlobeNewswire Inc. • 05/14/2024 03:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 09:00:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/10/2024 09:15:22 PM
- Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering • GlobeNewswire Inc. • 05/09/2024 12:00:12 AM
- Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo • GlobeNewswire Inc. • 04/15/2024 12:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:07 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:56:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:05:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/26/2024 10:09:03 PM
- Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress • GlobeNewswire Inc. • 01/25/2024 01:05:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM